Sign In
Buy ZYME
$22.86
-0.260 (-1.12%)
At Close: Jul 24, 2026
Huge Insider Buying: Victoria's Secret, Carl Icahn, and More
08:45am, Saturday, 15'th Mar 2025
Despite (or perhaps because of) the volatility in the stock market and uncertainty about the economy, insiders are still scooping up shares of certain stocks.
Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251
01:18pm, Thursday, 06'th Mar 2025
On Wednesday, Zymeworks Inc. ZYME released fourth-quarter financial results. The company reported an earnings loss of 31 cents per share, missing the consensus loss of 3 cents.
Zymeworks Inc. (ZYME) Q4 2024 Earnings Call Transcript
08:43pm, Wednesday, 05'th Mar 2025
Zymeworks Inc. (NASDAQ:ZYME ) Q4 2024 Earnings Conference Call March 5, 2025 4:30 PM ET Company Participants Shrinal Inamdar - Director, Investor Relations Leone Patterson - Executive Vice President,
Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates
06:16pm, Wednesday, 05'th Mar 2025
Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.20 per share a year ago.
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
04:05pm, Wednesday, 05'th Mar 2025
VANCOUVER, British Columbia, March 05, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherape
Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration
06:00am, Wednesday, 26'th Feb 2025
VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeut
Zymeworks Announces Participation in Upcoming Investor Conferences
06:00am, Tuesday, 25'th Feb 2025
VANCOUVER, British Columbia, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors
06:00am, Tuesday, 18'th Feb 2025
VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025
06:00am, Thursday, 13'th Feb 2025
VANCOUVER, British Columbia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
Zymeworks Announces Participation in Upcoming Investor Conferences
06:00am, Thursday, 30'th Jan 2025
VANCOUVER, British Columbia, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
3 Biotech Stocks With Notable Insider Buying
12:29pm, Wednesday, 22'nd Jan 2025
Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-c
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026
04:05pm, Wednesday, 08'th Jan 2025
VANCOUVER, British Columbia, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu
Wall Street Analysts Believe Zymeworks (ZYME) Could Rally 41.36%: Here's is How to Trade
11:06am, Tuesday, 07'th Jan 2025
The mean of analysts' price targets for Zymeworks (ZYME) points to a 41.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys
Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule
09:00am, Thursday, 19'th Dec 2024
The Zymeworks story over the last two years was one of transformation and execution. Ziihera (zanidatamab) was approved in November for the treatment of second line biliary tract cancer and Zymeworks
Zymeworks upgraded to Overweight from Neutral at JPMorgan
05:22am, Monday, 16'th Dec 2024
JPMorgan upgraded Zymeworks to Overweight from Neutral with an $18 price target.
